Allo-HSCT vs ASCT in Adult T-LBL

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Dec 15, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two types of stem cell transplants—autologous hematopoietic stem cell transplantation (ASCT) and allogeneic hematopoietic stem cell transplantation (Allo-HSCT)—to see which one is more effective for treating adult T Lymphoblastic Lymphoma (T-LBL). The goal is to find out which method helps patients stay healthy after their initial treatment. The trial is not yet recruiting participants, but it is looking for adults aged 18 to 65 who have recently been diagnosed with advanced T-LBL (stage III or IV) and have responded well to the first three rounds of chemotherapy.

To be eligible, participants must have a good performance status, meaning they should be able to carry out daily activities with little to no difficulty. They will need to provide consent to participate in the study. Unfortunately, those who are older than 65, have not responded well to their initial treatment, or have other serious health issues will not be able to join. If you participate, you can expect to receive either type of stem cell transplant and will be monitored closely by medical professionals throughout the process to ensure your safety and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1) Newly diagnosed T-LBL; 2) 18-65 years of age at the time of diagnosis; 3) Categorized into Ann-Arbor stage III or IV; 4) Achieving complete response (CR) after 3 courses of induction chemotherapies; 5) ECOG PS score 0 or 1; 6) It needs consent from the patients or/and legal guardian, and signature on the Informed Consent.
• Exclusion Criteria:
• • 1) Newly diagnosed T-LBL, but categorized into Ann-Arbor stage I or II; 2) \< 18 years, or older than 65 years at the time of diagnosis; 3) Achieving CR after 4 or more courses of induction chemotherapies, or could not achieve at least CR after induction chemotherapies; 4) with \> 25% BM involvement or \> 5% lymphoma cells in the peripheral blood; 5) ECOG PS score of 2 or more; 6) Patients with other comorbidities or mental diseases that influence the life safety and compliance of patients as well as affect informed consent, enrollment in the research, follow-up visit or result interpretation.